Management of Chronic Noncancer Pain in Depressed Patients

References

• . Bair MJ, Wu J, Damush TM, Sutherland JM, Kroenke K. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients. Psychosom Med. 2008; 70(8):890–897
   PubMed Web of Science ®Google Scholar
• . Castro M, Kraychete D, Daltro C, Lopes J, Menezes R, Oliveira I. Comorbid anxiety and depression disorders in patients with chronic pain. Arq Neuropsiquiatr. 2009; 67(4):982–985
   PubMed Web of Science ®Google Scholar
• . Leo RJ, Pristach CA, Streltzer J. Incorporating pain management training into the psychiatry residency curriculum. Acad Psychiatry. 2003; 27(1):1–11
   PubMedGoogle Scholar
• . Sullivan MD, Edlund MJ, Steffick D, Unützer J. Regular use of prescribed opioids: Association with common psychiatric disorders. Pain. 2005; 119(1–3):95–103
   PubMed Web of Science ®Google Scholar
• . Shaw WS, Means-Christensen AJ, Slater MA, . Psychiatric disorders and risk of transition to chronicity in men with first onset low back pain. Pain Med. 2010; 11(9):1391–1400
   PubMedGoogle Scholar
• . Currie SR, Wang J. Chronic back pain and major depression in the general Canadian population. Pain. 2004; 107(1–2):54–60
   PubMed Web of Science ®Google Scholar
• . Merikangas KR, Ames M, Cui L, . The impact of comorbidity of mental and physical conditions on role disability in the US adult household population. Arch Gen Psychiatry. 2007; 64(10):1180–1188
   PubMedGoogle Scholar
• . Cone EJ, Caplan YH. Urine toxicology testing in chronic pain management. Postgrad Med. 2009; 121(4):91–102
   PubMed Web of Science ®Google Scholar
• . Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract. 2008; 4(2):4–25
   PubMedGoogle Scholar
• . Larson AM, Polson J, Fontana RJ, . Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology. 2005; 42(6):1364–1372
   PubMed Web of Science ®Google Scholar
• . Maloney E, Degenhardt L, Darke S, Nelson EC. Are non-fatal opioid overdoses misclassified suicide attempts? Comparing the associated correlates. Addict Behav. 2009; 34(9):723–729
   PubMedGoogle Scholar
• . Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010; 27(5):417–433
   PubMed Web of Science ®Google Scholar
• . Malhotra S, Karan RS, Pandhi P, Jain S. Drug related medical emergencies in the elderly: Role of adverse drug reactions and non-compliance. Postgrad Med J. 2001; 77(913):703–707
   PubMed Web of Science ®Google Scholar
• . Tulner LR, Frankfort SV, Gijsen GJ, van Campen JP, Koks CH, Beijnen JH. Drug-drug interactions in a geriatric outpatient cohort: Prevalence and relevance. Drugs Aging. 2008; 25(4):343–355
   PubMed Web of Science ®Google Scholar
• . Attal N, Cruccu G, Baron R, ; European Federation of Neurological Societies. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010; 17(9): e1113–e1188
   PubMed Web of Science ®Google Scholar
• . Kadian (morphine sulfate sustained release capsules) [package insert]. Piscataway, NJ: Alpharma; 2007
   Google Scholar
• . Dilaudid-HP (hydromorphone hydrochloride) [package insert]. North Chicago, IL: Abbott Laboratories; 2008
   Google Scholar
• . Duragesic (fentanyl transdermal system) [package insert]. Ortho-McNeil-Raritan, NJ: Janssen Pharmaceuticals, Inc; 2009
   Google Scholar
• . OxyContin (oxycodone HCl controlled-release tablets) [package insert]. Purdue Stamford, CT: Pharma LP; 2010
   Google Scholar
• . Opana ER (oxymorphone hydrochloride extended-release tablets) [package isnert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc; 2010
   Google Scholar
• . Barkin RL, Barkin SJ. Reexamining the elderly patient's presentation with depression. Prim Care Companion J Clin Psychiatry. 2008; 10(5):415–416
   PubMedGoogle Scholar
• . Avasarala JR, Cross AH, Trinkaus K. Comparative assessment of Yale Single Question and Beck Depression Inventory Scale in screening for depression in multiple sclerosis. Mult Scler. 2003; 9(3):307–310
   PubMed Web of Science ®Google Scholar
• . Glombiewski JA, Hartwich-Tersek J, Rief W. Depression in chronic back pain patients: Prediction of pain intensity and pain disability in cognitive-behavioral treatment. Psychosomatics. 2010; 51(2): 130–136
   PubMed Web of Science ®Google Scholar
• . Hall AM, Kamper SJ, Maher CG, Latimer J, Ferreira ML, Nicholas MK. Symptoms of depression and stress mediate the effect of pain on disability. Pain. 2011; 152(5):1044–1051
   PubMed Web of Science ®Google Scholar
• . Pincus T, Burton AK, Vogel S, Field AP. A systematic review of psychological factors as predictors of chronicity/disability in prospective cohorts of low back pain. Spine. 2002; 27(5):E109–E120
   PubMedGoogle Scholar
• . Ang DC, Bair MJ, Damush TM, Wu J, Tu W, Kroenke K. Predictors of pain outcomes in patients with chronic musculoskeletal pain co-morbid with depression: Results from a randomized controlled trial. Pain Med. 2010; 11(4):482–491
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Cash KA, Damron KS, Manchukonda R, Pampati V, McManus CD. Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician. 2006; 9(3):215–225
   PubMedGoogle Scholar
• . Manchikanti L, Damron KS, McManus CD, Barnhill RC. Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective, observational study. Pain Physician. 2004; 7(4):431–437
   PubMedGoogle Scholar
• . Manchikanti L, Pampati V, Damron KS, Beyer CD, Barnhill RC, Fellows B. Prevalence of prescription drug abuse and dependency in patients with chronic pain in western Kentucky. J Ky Med Assoc. 2003; 101(11):511–517
   PubMedGoogle Scholar
• . Kirsh KL, Jass C, Bennett DS, Hagen JE, Passik SD. Initial development of a survey tool to detect issues of chemical coping in chronic pain patients. Palliat Support Care. 2007; 5(3):219–226
   PubMedGoogle Scholar
• . Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain. 2007; 23(4):307–315
   PubMed Web of Science ®Google Scholar
• . Ilgen MA, Zivin K, McCammon RJ, Valenstein M. Pain and suicidal thoughts, plans and attempts in the United States. Gen Hosp Psychiatry. 2008; 30(6):521–527
   PubMedGoogle Scholar
• . Neufeld E, O'Rourke N. Impulsivity and hopelessness as predictors of suicide-related ideation among older adults. Can J Psychiatry. 2009; 54(10):684–692
   PubMed Web of Science ®Google Scholar
• . Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: A rational approach to the treatment of chronic pain. Pain Med. 2005; 6(2):107–112
   PubMed Web of Science ®Google Scholar
• . Camidge DR, Wood RJ, Bateman DN. The epidemiology of self-poisoning in the UK. Br J Clin Pharmacol. 2003; 56(6):613–619
   PubMed Web of Science ®Google Scholar
• . Berndt S, Maier C, Schütz H W. Polymedication and medication compliance in patients with chronic non-malignant pain. Pain. 1993; 52(3):331–339
   PubMed Web of Science ®Google Scholar
• . Parsells Kelly J, Cook SF, . Prevalence and characteristics of opioid use in the US adult population. Pain. 2008; 138(3):507–513
   PubMed Web of Science ®Google Scholar
• . Preskorn SH, Silkey B, Shah R, . Complexity of medication use in the Veterans Affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers. J Psychiatr Pract. 2005; 11(1):5–15
   PubMedGoogle Scholar
• . Goldberg JF, Brooks JO 3rd, Kurita K, . Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: Findings from the STEP-BD. J Clin Psychiatry. 2009; 70(2): 155–162
   PubMed Web of Science ®Google Scholar
• . Pergolizzi JV, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph R, Summers KH. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: Incremental risk of multiple prescriptions. Pain Pract. 2011; 11(4):325–336
   PubMed Web of Science ®Google Scholar
• . American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009; 57(8):1331–1346
   PubMed Web of Science ®Google Scholar
• . Chou R, Qaseem A, Snow V, ; Clinical efficacy Assessment Subcommittee of the American College of Physicians; American College of Physicians; American Pain Society Low Back Pain Guidelines Panel. Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007; 147(7):478–491
   PubMed Web of Science ®Google Scholar
• . Zhang W, Moskowitz RW, Nuki G, . OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16(2):137–162
   PubMed Web of Science ®Google Scholar
• . Chou R, Fanciullo GJ, Fine PG, ; American Pain Society—American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2):113–130
   PubMed Web of Science ®Google Scholar
• . de Miquel CA, Campayo JG, Flórez MT, . Interdisciplinary consensus document for the treatment of fibromyalgia. Actas Esp Psiquiatr. 2010; 38(2):108–120
   PubMed Web of Science ®Google Scholar
• . American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx. Accessed June 30, 2011
   Google Scholar
• . Lam RW, Kennedy SH, Grigoriadis S, . Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117( suppl 1):S26–S43
   PubMed Web of Science ®Google Scholar
• . Dworkin RH, O'Connor AB, Backonja M, . Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007; 132(3):237–251
   PubMed Web of Science ®Google Scholar
• . Chappell AS, Desaiah D, Liu-Seifert H, . A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract. 2011; 11(1):33–41
   PubMed Web of Science ®Google Scholar
• . Chappell AS, Ossanna MJ, Liu-Seifert H, . Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial. Pain. 2009; 146(3):253–260
   PubMed Web of Science ®Google Scholar
• . Sullivan MD, Bentley S, Fan MY, Gardner G. A single-blind, placebo run-in study of duloxetine for activity-limiting osteoarthritis pain. J Pain. 2009; 10(2):208–213
   PubMed Web of Science ®Google Scholar
• . Sullivan M, Bentley S, Fan MY, Gardner G. A single-blind placebo run-in study of venlafaxine XR for activity-limiting osteoarthritis pain. Pain Med. 2009; 10(5):806–812
   PubMed Web of Science ®Google Scholar
• . Zhang W, Doherty M, Leeb BF, . EULAR evidence based recommendations for the management of hand osteoarthritis: Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007; 66(3): 377–388
   PubMed Web of Science ®Google Scholar
• . Zhang W, Nuki G, Moskowitz RW, . OARSI recommendations for the management of hip and knee osteoarthritis: Part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18(4): 476–499
   PubMed Web of Science ®Google Scholar
• . Dworkin RH, O'Connor AB, Audette J, . Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2010; 85( 3 suppl):S3–S14
   PubMed Web of Science ®Google Scholar
• . Chun LJ, Tong MJ, Busuttil RW, Hiatt JR. Acetaminophen hepatotoxicity and acute liver failure. J Clin Gastroenterol. 2009; 43(4): 342–349
   PubMed Web of Science ®Google Scholar
• . Watkins PB, Kaplowitz N, Slattery JT, . Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: A randomized controlled trial. JAMA. 2006; 296(1):87–93
   PubMed Web of Science ®Google Scholar
• . Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994; 272(23):1845–1850
   PubMed Web of Science ®Google Scholar
• . Associated Press. Muscle-pain reliever is blamed for Staten Island runner's death. New York Times. June 10, 2007
   Google Scholar
• . Chan T Y. Potential dangers from topical preparations containing methyl salicylate. Hum Exp Toxicol. 1996; 15(9):747–750
   PubMed Web of Science ®Google Scholar
• . Chan TY. The risk of severe salicylate poisoning following the ingestion of topical medicaments or aspirin. Postgrad Med J. 1996; 72(844):109–112
   PubMed Web of Science ®Google Scholar
• . Pec J, Strmenova M, Palencarova E, . Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis. Cutis. 1992; 50(4):307–309
   PubMed Web of Science ®Google Scholar
• . Kuhn MA. Herbal remedies: Drug-herb interactions. Crit Care Nurse. 2002; 22(2):22–28, 30, 32; quiz 34–35
   PubMedGoogle Scholar
• . Loke YK, Trivedi AN, Singh S. Meta-analysis: Gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008; 27(1):31–40
   PubMed Web of Science ®Google Scholar
• . Barkin RL, Beckerman M, Blum SL, Clark FM, Koh EK, Wu DS. Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? Drugs Aging. 2010; 27(10):775–789
   PubMed Web of Science ®Google Scholar
• . Kienzler J, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol New Drugs. 2010; 50:50–61
   Google Scholar
• . Altman RD, Dreiser RL, Fisher CL, Chase WF, Dreher DS, Zacher J. Diclofenac sodium gel in patients with primary hand osteoarthritis: A randomized, double-blind, placebo-controlled trial. J Rheumatol. 2009; 36(9):1991–1999
   PubMed Web of Science ®Google Scholar
• . Baraf HS, Gold MS, Clark MB, Altman RD. Safety and efficacy of topical diclofenac sodium 1% gel in knee osteoarthritis: A randomized controlled trial. Phys Sportsmed. 2010; 38(2):19–28
   PubMed Web of Science ®Google Scholar
• . Barthel HR, Haselwood D, Longley S, Gold MS, Altman RD. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009; 39(3):203–212
   PubMed Web of Science ®Google Scholar
• . Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009; 143(3):238–245
   PubMed Web of Science ®Google Scholar
• . Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J Rheumatol. 2004; 31(10):2002–2012
   PubMed Web of Science ®Google Scholar
• . Zacher J, Burger KF, Farber L, Gräve M, Abberger H, Bertsch K. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes). Double-blind, controlled, randomized study. Aktuelle Rheumatologie. 2001; 26:7–14
   Web of Science ®Google Scholar
• . Baraf HS, Gold MS, Petruschke RA, Wieman MS. The tolerability of topical diclofenac sodium 1% gel for osteoarthritis in seniors and patients with comorbidities. J Am Med Dir Assoc. In press
   Google Scholar
• . Barkin RL. Nonopioid analgesics for osteoarthritis: Availability of topical NSAIDs. J Pain Palliat Care Pharmacother. 2010; 24(2): 180–181
   PubMedGoogle Scholar
• . Zacher J, Burger KF, Farber L, Grave M, Abberger H, Bertsch K. Topical diclofenac Emulgel versus oral ibuprofen in the treatment of active osteoarthritis of the finger joints (Heberden's and/or Bouchard's nodes). Double-blind, controlled, randomized study. Postgrad Med. In press
   Google Scholar
• . Attal N, Guirimand F, Brasseur L, Gaude V, Chauvin M, Bouhassira D. Effects of IV morphine in central pain: A randomized placebo-controlled study. Neurology. 2002; 58(4):554–563
   PubMedGoogle Scholar
• . Argoff CE, Galer BS, Jensen MP, Oleka N, Gammaitoni AR. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: Assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004; 20( suppl 2):S21–S28
   PubMed Web of Science ®Google Scholar
• . Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: An open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009; 25(7):1663–1676
   PubMed Web of Science ®Google Scholar
• . Baron R, Mayoral V, Leijon G, Binder A, Steigerwald I, Serpell M. efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: Interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 2009; 29(4):231–241
   PubMed Web of Science ®Google Scholar
• . Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996; 65(1):39–44
   PubMed Web of Science ®Google Scholar
• . Fishbain DA, Lewis JE, Cole B, Cutler B, Rosomoff HL, Rosomoff RS. Lidocaine 5% patch: An open-label naturalistic chronic pain treatment trial and prediction of response. Pain Med. 2006; 7(2):135–142
   PubMedGoogle Scholar
• . Galer BS, Gammaitoni AR, Oleka N, Jensen MP, Argoff CE. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin. 2004; 20( suppl 2):S5–S12
   PubMed Web of Science ®Google Scholar
• . White WT, Patel N, Drass M, Nalamachu S. Lidocaine patch 5% with systemic analgesics such as gabapentin: A rational polypharmacy approach for the treatment of chronic pain. Pain Med. 2003; 4(4): 321–330
   PubMed Web of Science ®Google Scholar
• . Barbano RL, Herrmann DN, Hart-Gouleau S, Pennella-Vaughan J, Lodewick PA, Dworkin RH. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004; 61(6):914–918
   PubMedGoogle Scholar
• . Meier T, Wasner G, Faust M, . efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: A randomized, double-blind, placebo-controlled study. Pain. 2003; 106(1–2):151–158
   PubMed Web of Science ®Google Scholar
• . Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: An open-label study. Clin J Pain. 2000; 16(3):205–208
   PubMed Web of Science ®Google Scholar
• . Herrmann DN, Barbano RL, Hart-Gouleau S, Pennella-Vaughan J, Dworkin RH. An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med. 2005; 6(5):379–384
   PubMed Web of Science ®Google Scholar
• . Fleming JA, O'Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag. 2009; 14(5): 381–388
   PubMedGoogle Scholar
• . Campbell BJ, Rowbotham M, Davies PS, Jacob P 3rd, Benowitz NL. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 2002; 91(5):1343–1350
   PubMed Web of Science ®Google Scholar
• . Gammaitoni AR, Davis M W. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002; 36(2):236–240
   PubMed Web of Science ®Google Scholar
• . Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study. Pain. 1999; 80(3):533–538
   PubMed Web of Science ®Google Scholar
• . Berrocoso E, Sanchez-Blazquez P, Garzón J, Mico JA. Opiates as antidepressants. Curr Pharm Des. 2009; 15(14):1612–1622
   PubMed Web of Science ®Google Scholar
• . Jutkiewicz EM. The antidepressant-like effects of delta-opioid receptor agonists. Mol Interv. 2006; 6(3):162–169
   PubMedGoogle Scholar
• . Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008; 98(3):191–202
   PubMed Web of Science ®Google Scholar
• . Schoedel KA, McMorn S, Zerbe K, Chakraborty B, Potts SL, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone. J Opioid Manag. 2010; 13(6)561–573
   Google Scholar
• . Brown RM, Lawrence AJ. Neurochemistry underlying relapse to opiate seeking behaviour. Neurochem Res. 2009; 34(10):1876–1887
   PubMedGoogle Scholar
• . Ross S, Peselow E. The neurobiology of addictive disorders. Clin Neuropharmacol. 2009; 32(5):269–276
   PubMed Web of Science ®Google Scholar
• . Zahm DS. Pharmacotherapeutic approach to the treatment of addiction: Persistent challenges. Mo Med. 2010; 107(4):276–280
   PubMedGoogle Scholar
• . Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain. 1999; 15(3):184–191
   PubMed Web of Science ®Google Scholar
• . American Academy of Pain Medicine and American Pain Society. The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain. 1997; 13(1):6–8
   PubMedGoogle Scholar
• . Manchikanti L, Atluri S, Trescot AM, Giordano J. Monitoring opioid adherence in chronic pain patients: Tools, techniques, and utility. Pain Physician. 2008; 11( 2 suppl):S155–S180
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Singh V, Damron KS, Beyer CD, Pampati V. Screening for controlled substance abuse in interventional pain management settings: Evaluation of an assessment tool. Pain Physician. 2003; 6(4):425–433
   PubMedGoogle Scholar
• . Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: Systematic review of efficacy and safety. Pain. 2004; 112(3):372–380
   PubMed Web of Science ®Google Scholar
• . Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: A Scientific statement from the American Heart Association. Circulation. 2007; 115(12):1634–1642
   PubMed Web of Science ®Google Scholar
• . Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. CMAJ. 2006; 174(11):1589–1594
   PubMed Web of Science ®Google Scholar
• . Kennedy SE, Koeppe RA, Young EA, Zubieta JK. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry. 2006; 63(11):1199–1208
   PubMed Web of Science ®Google Scholar
• . Bodkin JA, Zornberg GL, Lukas SE, Cole JO. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol. 1995; 15(1):49–57
   PubMed Web of Science ®Google Scholar
• . Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psychiatry. 1999; 156(12):2017
   PubMedGoogle Scholar
• . Smith HS. Opioid metabolism. Mayo Clin Proc. 2009; 84(7):613–624
   PubMed Web of Science ®Google Scholar
• . Leppert W. CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology. 2011; 87(5–6):274–285
   PubMed Web of Science ®Google Scholar
• . Ultram ER (tramadol hydrochloride) [package insert]. Raritan, NJ: Ortho-McNeil; 2008
   Google Scholar
• . NUCYNTA (tapentadol immediate release oral tablets) [package insert]. Raritan, NJ: PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc; 2008
   Google Scholar
• . Butrans Transdermal System (buprenorphine) [package insert]. Stamford, CT: Purdue Pharma LP; 2010
   Google Scholar
• . Wedam EF, Bigelow GE, Johnson RE, Nuzzo PA, Haigney MC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007; 167(22):2469–2475
   PubMedGoogle Scholar
• . Hydrocodone bitartate and acetaminophen tablets [package insert]. Corona, CA: Watson Pharma; 2006
   Google Scholar
• . Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin. 2008; 24(1):297–305
   PubMed Web of Science ®Google Scholar
• . Fiske WD, Jobes J, Xiang Q, Chang S, Benedek IH. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets. Ann Pharmacother. In press
   Google Scholar
• . Johnson F, Wagner G, Sun S, Stauffer J. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules. J Pain. 2008; 9(4):330–336
   PubMedGoogle Scholar
• . Barkin RL, Shirazi D, Kinzler E. Effect of ethanol on the release of morphine sulfate from Oramorph SR tablets. Am J Ther. 2009; 16(6): 482–486
   PubMedGoogle Scholar
• . Traynor MJ, Brown MB, Pannala A, Beck P, Martin GP. Influence of alcohol on the release of tramadol from 24-h controlled-release formulations during in vitro dissolution experiments. Drug Dev Ind Pharm. 2008; 34(8):885–889
   PubMed Web of Science ®Google Scholar
• . Clark MR, Treisman GJ. Optimizing treatment with opioids and beyond. Adv Psychosom Med. 2011; 30:92–112
   PubMedGoogle Scholar
• . Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008; 9(4):360–372
   PubMed Web of Science ®Google Scholar
• . Butler SF, Budman SH, Fernandez KC, . Development and validation of the Current Opioid Misuse Measure. Pain. 2007; 130(1–2):144–156
   PubMed Web of Science ®Google Scholar
• . Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the Opioid Risk Tool. Pain Med. 2005; 6(6):432–442
   PubMed Web of Science ®Google Scholar
• . Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K. Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Physician. 2006; 9(1):57–60
   PubMedGoogle Scholar
• . Gourlay DL, Heit HA, Caplan YH. Urine Drug Testing in Clinical Practice: The Art and Science of Patient Care. 4th ed: California Academy of Family Physicians; 2010
   Google Scholar
• . Katz N. Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep. 2008; 10(1):11–18
   PubMedGoogle Scholar
• . Smith HS, Barkin RL. Fibromyalgia syndrome: A discussion of the syndrome and pharmacotherapy. Dis Mon. 2011; 57(5):248–285
   PubMed Web of Science ®Google Scholar
• . Flockhart DA. Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. http://medicine.iupui.edu/flockhart/table.htm. Accessed June 16, 2011
   Google Scholar